Somatic mutations on glycine 34 of histone H3 (H3G34) cause pediatric cancers， but the underlying oncogenic mechanism remains unknown. We demonstrate that substituting H3G34 with arginine， valine， or aspartate (H3G34R/V/D)， which converts the non-side chain glycine to a large side chain-containing residue， blocks H3 lysine 36 (H3K36) dimethylation and trimethylation by histone methyltransferases， including SETD2， an H3K36-specific trimethyltransferase. Our structural analysis reveals that the H3 "G33-G34" motif is recognized by a narrow substrate channel， and that H3G34/R/V/D mutations impair the catalytic activity of SETD2 due to steric clashes that impede optimal SETD2-H3K36 interaction. H3G34... More
Somatic mutations on glycine 34 of histone H3 (H3G34) cause pediatric cancers， but the underlying oncogenic mechanism remains unknown. We demonstrate that substituting H3G34 with arginine， valine， or aspartate (H3G34R/V/D)， which converts the non-side chain glycine to a large side chain-containing residue， blocks H3 lysine 36 (H3K36) dimethylation and trimethylation by histone methyltransferases， including SETD2， an H3K36-specific trimethyltransferase. Our structural analysis reveals that the H3 "G33-G34" motif is recognized by a narrow substrate channel， and that H3G34/R/V/D mutations impair the catalytic activity of SETD2 due to steric clashes that impede optimal SETD2-H3K36 interaction. H3G34R/V/D mutations also block H3K36me3 from interacting with mismatch repair (MMR) protein MutSα， preventing the recruitment of the MMR machinery to chromatin. Cells harboring H3G34R/V/D mutations display a mutator phenotype similar to that observed in MMR-defective cells. Therefore， H3G34R/V/D mutations promote genome instability and tumorigenesis by inhibiting MMR activity.
